EPCORITAMAB

EPCORITAMAB

Injection

Epcoritamab-bysp is a bispecific CD20-directed CD3 T-cell engager; it is a humanized bispecific IgG1 antibody. Epcoritamab-bysp is manufactured in Chinese hamster ovary (CHO) cells using recombinant DNA technology and has an approximate molecular weight of 149 kDa
Injection: 4 mg/0.8 mL in a single-dose vial. Dilute prior to use. Injection: 48 mg/0.8 mL in a single-dose vial.
Patients should be hospitalized for 24 hours after administration of the Cycle 1 Day 15 dosage of 48 mg. • Administer premedications and prophylaxis as recommended. • Dosages of EPKINLY 0.16 mg and 0.8 mg require dilution prior to administration.
EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy